Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dynein axonemal heavy chain 14 (DNAH14)
- Target
- DNAH14
- Molecular classification
- Motor protein, Microtubule-associated protein, ATPase
01
Overview
Dynein axonemal heavy chain 14 is a force-generating protein found in motile cilia and flagella, encoded by the DNAH14 gene in humans[1][2][6]. It belongs to the family of axonemal dyneins, which are large motor ATPases that drive the beating of cilia and flagella by moving along microtubules[1][2]. DNAH14 is critical for generating movement towards the minus ends of microtubules and is implicated in processes such as mucociliary clearance in the respiratory tract and sperm motility[1]. Mutations in DNAH14 have been associated with neurodevelopmental disorders and other conditions involving ciliary dysfunction[3]. This protein is not currently considered a therapeutic target, nor are there any known direct pharmacological modulators.
- Other names
- C1orf67Dnahc14HL-18HL18DKFZp781B1548MGC27277Axonemal beta dynein heavy chain 14Ciliary dynein heavy chain 14Dynein heavy chain 14, axonemalDynein, axonemal, heavy polypeptide 14
02
Mechanism of action
Not applicable (no known drug interactions)
03
Biological functions
Microtubule-based movementForce generation for ciliary and flagellar motilitySperm flagellar assembly and motilityCiliary movement in respiratory and other epithelia
04
Disease associations
Neurodevelopmental disorders (e.g., seizures, global developmental delay, microcephaly, hypotonia)[3]Hydrops fetalis, nonimmune[1]Brain compression[1]Potential role in ciliopathies
05
Safety considerations
None established (not a therapeutic target; safety concerns not described)
06
Biomarkers
None established; DNAH14 variants have been identified in research as genetic lesions in certain neurodevelopmental disorders and ciliopathies, but it is not currently a validated biomarker for patient selection or monitoring[3]
Beyond the preview
Go deeper on Dynein axonemal heavy chain 14 (DNAH14).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dynein axonemal heavy chain 14 (DNAH14).